Wechselwirkungen · Akynzeo
Akynzeo 300 mg/0.5 mg hard capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-130692 · Präparat HOS-096947
Erythromycin and Midazolam Exposure to erythromycin and midazolam was increased approximately 1.3 and 2.4 fold, respectively, when each was co-administered with netupitant. These effects were not considered clinically important. The pharmacokinetic profile of netupitant was unaffected by the concomitant administration of either midazolam or erythromycin. The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolised via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these active substances with netupitant/palonosetron capsules.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alprazolam (HOS-086171) erythromycin (HOS-084514) triazolam (HOS-086168) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T11:52:00Z · SHA-256 d3ff78e9e4d5b08bc98e527fab724082b02f5be1899a4d4f9c683d723854e46c · Passage 815f80ecceeac5979ea026405e16057a76e58abbe322c9596d900e9b03769eea · Zeichen 2735–3338 im Abschnitt